1. Home
  2. MCO vs VRTX Comparison

MCO vs VRTX Comparison

Compare MCO & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moody's Corporation

MCO

Moody's Corporation

N/A

Current Price

$509.36

Market Cap

83.4B

Sector

Finance

ML Signal

N/A

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

N/A

Current Price

$551.72

Market Cap

135.6B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
MCO
VRTX
Founded
1900
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
EDP Services
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
83.4B
135.6B
IPO Year
1998
2006

Fundamental Metrics

Financial Performance
Metric
MCO
VRTX
Price
$509.36
$551.72
Analyst Decision
Buy
Buy
Analyst Count
24
32
Target Price
$552.48
★ $592.36
AVG Volume (30 Days)
849.5K
★ 1.6M
Earning Date
10-21-2026
11-02-2026
Dividend Yield
★ 0.81%
N/A
EPS Growth
21.40
★ 836.54
EPS
★ 12.98
10.90
Revenue
★ $4,204,100,000.00
$2,488,652,000.00
Revenue This Year
$6.58
$10.42
Revenue Next Year
$6.68
$10.38
P/E Ratio
★ $39.10
$50.19
Revenue Growth
N/A
★ 46.20
52 Week Low
$402.28
$412.27
52 Week High
$546.88
$568.67

Technical Indicators

Market Signals
Indicator
MCO
VRTX
Relative Strength Index (RSI) 60.53 59.00
Support Level $431.44 $461.04
Resistance Level $521.99 $568.67
Average True Range (ATR) 13.96 18.66
MACD 2.93 2.45
Stochastic Oscillator 70.17 69.21

Price Performance

Historical Comparison
MCO
VRTX

About MCO Moody's Corporation

Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and often (depending on bond issuance levels) a majority of the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Share on Social Networks: